Phase II study of pembrolizumab (MK-3475) for relapsed/refractory classical Hodgkin Lymphoma (r/r cHL): keynote-087

por Chen, Robert, Armand, Phillippe, Fanale, Michelle A, Ribrag, Vincent, Zinzani, Pier Luigi, Ricart, Alejandro D, Thompson, Seth, Balakumaran, Arun, Molin, Daniel, Shipp, Margaret A, Moskowitz, Craig H
Publicado 2015